Clinical pharmacology of antifungal compounds

被引：93

作者：

Groll, AH

Gea-Banacloche, JC

Glasmacher, A

Just-Nuebling, G

Maschmeyer, G

Walsh, TJ

机构：

[1] Univ Munster, Med Ctr, Ctr Bone Marrow Transplantat, Infect Dis Res Program, D-48149 Munster, Germany

[2] Univ Munster, Med Ctr, Dept Pediat Hematol Oncol, D-48149 Munster, Germany

[3] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA

[4] Univ Bonn, Dept Internal Med 1, D-53121 Bonn, Germany

[5] Goethe Univ Frankfurt, Dept Internal Med, Div Infect Dis, D-60590 Frankfurt, Germany

[6] Univ Hosp Berlin, Charite, Dept Internal Med, Div Hematol & Oncol, D-13353 Berlin, Germany

[7] NCI, Pediat Oncol Branch, Immunocompromised Host Sect, NIH, Bethesda, MD 20892 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2003年 / 17卷 / 01期

关键词：

D O I：

10.1016/S0891-5520(02)00068-5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Prompted by the worldwide surge in fungal infections, the past decade has witnessed a considerable expansion in antifungal drug research. New compounds have entered the clinical arena, and major progress has been made in defining paradigms of antifungal therapies. This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients.

引用

页码：159 / +

页数：34

共 131 条

[1] Congestive heart failure associated with itraconazole
Ahmad, SR
Singer, SJ
Leissa, BG
[J]. LANCET, 2001, 357 (9270) : 1766 - 1767
[2] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
Ally, R
Schürmann, D
Kreisel, W
Carosi, G
Aguirrebengoa, K
Dupont, B
Hodges, M
Troke, P
Romero, AJ
[J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) : 1447 - 1454
[3] SAFETY, PLASMA-CONCENTRATIONS, AND EFFICACY OF HIGH-DOSE FLUCONAZOLE IN INVASIVE MOLD INFECTIONS
ANAISSIE, EJ
KONTOYIANNIS, DP
HULS, C
VARTIVARIAN, SE
KARL, C
PRINCE, RA
BOSSO, J
BODEY, GP
[J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02) : 599 - 602
[4] Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
Anaissie, EJ
Darouiche, RO
AbiSaid, D
Uzun, O
Mera, J
Gentry, LO
Williams, T
Kontoyiannis, DP
Karl, CL
Bodey, GP
[J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) : 964 - 972
[5] Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D
Stamsted, T
Conklin, R
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 922 - 926
[6] Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases
Arathoon, EG
Gotuzzo, E
Noriega, LM
Berman, RS
DiNubile, MJ
Sable, CA
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) : 451 - 457
[7] AMPHOTERICIN-B PHARMACOKINETICS IN HUMANS
ATKINSON, AJ
BENNETT, JE
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1978, 13 (02) : 271 - 276
[8] BEALE M, 2001, 41 INT C ANT AG CHEM
[9] COMPARISON OF AMPHOTERICIN-B ALONE AND COMBINED WITH FLUCYTOSINE IN THE TREATMENT OF CRYPTOCCAL MENINGITIS
BENNETT, JE
DISMUKES, WE
DUMA, RJ
MEDOFF, G
SANDE, MA
GALLIS, H
LEONARD, J
FIELDS, BT
BRADSHAW, M
HAYWOOD, H
MCGEE, ZA
CATE, TR
COBBS, CG
WARNER, JF
ALLING, DW
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (03) : 126 - 131
[10] ITRACONAZOLE FOR EXPERIMENTAL PULMONARY ASPERGILLOSIS - COMPARISON WITH AMPHOTERICIN-B, INTERACTION WITH CYCLOSPORINE-A, AND CORRELATION BETWEEN THERAPEUTIC RESPONSE AND ITRACONAZOLE CONCENTRATIONS IN PLASMA
BERENGUER, J
ALI, NM
ALLENDE, MC
LEE, J
GARRETT, K
BATTAGLIA, S
PISCITELLI, SC
RINALDI, MG
PIZZO, PA
WALSH, TJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) : 1303 - 1308

← 1 2 3 4 5 6 7 8 9 10 →